- Home
- GRF vs RNXT Comparison
GRF vs RNXT Comparison
Compare GRF & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- RNXT
- Stock Information
- Founded
- GRF 1989
- RNXT 2012
- Country
- GRF United States
- RNXT United States
- Employees
- GRF N/A
- RNXT N/A
- Industry
- GRF Finance/Investors Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- GRF Finance
- RNXT Health Care
- Exchange
- GRF Nasdaq
- RNXT Nasdaq
- Market Cap
- GRF 39.3M
- RNXT 44.6M
- IPO Year
- GRF N/A
- RNXT 2021
- Fundamental
- Price
- GRF $10.43
- RNXT $0.94
- Analyst Decision
- GRF
- RNXT Strong Buy
- Analyst Count
- GRF 0
- RNXT 2
- Target Price
- GRF N/A
- RNXT $7.25
- AVG Volume (30 Days)
- GRF 3.0K
- RNXT 231.0K
- Earning Date
- GRF 01-01-0001
- RNXT 08-14-2025
- Dividend Yield
- GRF 3.70%
- RNXT N/A
- EPS Growth
- GRF N/A
- RNXT N/A
- EPS
- GRF 1.16
- RNXT N/A
- Revenue
- GRF N/A
- RNXT $662,000.00
- Revenue This Year
- GRF N/A
- RNXT $3,104.65
- Revenue Next Year
- GRF N/A
- RNXT $301.89
- P/E Ratio
- GRF $8.15
- RNXT N/A
- Revenue Growth
- GRF N/A
- RNXT N/A
- 52 Week Low
- GRF $7.93
- RNXT $0.75
- 52 Week High
- GRF $10.19
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- GRF 65.01
- RNXT 35.66
- Support Level
- GRF $9.95
- RNXT $0.80
- Resistance Level
- GRF $10.98
- RNXT $0.95
- Average True Range (ATR)
- GRF 0.12
- RNXT 0.10
- MACD
- GRF 0.07
- RNXT -0.01
- Stochastic Oscillator
- GRF 76.70
- RNXT 22.81
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.